At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 32 enrolled
Drug / intervention
Pexidartinibdrug
Likely dose
Pexidartinib 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4, Multicenter Study to Evaluate Discontinuation and Re-Treatment in Subjects With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib
In Brief
A Phase 4 clinical trial evaluating Pexidartinib for Tenosynovial Giant Cell Tumor. Completed, enrolled 32 participants across 16 sites in 7 countries.
Detailed Summary
This study is designed to evaluate the discontinuation/re-treatment of pexidartinib therapy in previously treated participants with tenosynovial giant cell tumor (TGCT).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTenosynovial Giant Cell Tumor
CountriesAustralia, Hungary, Italy, Netherlands, Spain, Taiwan, United States
Collaborators--
Timeline
Phase 4CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartOct 2020
Primary CompletionJul 2023
TodayJul 2026
First PostedAug 26, 2020
Enrollment StartOct 20, 2020
Primary CompletionJul 7, 2023
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 5.9 years ago
Interventions
Pexidartinibdrug
200 mg capsules administered orally twice daily on an empty stomach (at least 1 hour before or at least 2 hours after a meal or snack)